NF1 and cancer: Most of the HER2 mutations (95.5%) occurred in the subclone and more likely co-occurred with mutations in other genes such as TP53, PIK3CA, MLL3, FAT2, NF1 and GATA3. Therefore, we hypothesized that HER2 mutations might be induced by anti-cancer therapies.